Compare Dolby Laboratories, Inc. (DLB) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Novavax Inc — how do they compare? Dolby Laboratories, Inc. trades at $58.9 (market cap $5.47B), while Novavax Inc trades at $11.11 (market cap $1.82B). The key difference: Dolby Laboratories, Inc. is far larger — about 3× Novavax Inc's market cap, and Dolby Laboratories, Inc. pays a 2.46% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Novavax Inc for 59 Days on average.
| DLB | NVAX | |
|---|---|---|
Market Cap | $5.47B | $1.82B |
Volume | 1,058,284 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $70.09 | $12.56 |
52-Week Low | $48.51 | $6.22 |
Typical Hold Time | 98 Days | 59 Days |
Enterprise Value | $4.85B | $1.39B |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.35, down 0.19% with bearish technical signals. The company maintains strong profitability with 87.61% gross margins and has beaten earnings estimates for three consecutive quarters. Recent developments include expanded partnerships with Meta and leadership transition to new CEO Marc Whitten. Cash flow improved significantly in 2025 with $472M operating cash flow.
DLB presents a mixed outlook with strong fundamentals but technical weakness. The 47% upside to $90.33 consensus target offers potential, though near-term execution risks and licensing volatility remain concerns. Revenue stability around $1.3B and premium valuation metrics require continued innovation execution to justify current multiples.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
